Abstract: Disclosed herein are molecules and pharmaceutical compositions that mediate RNA interference against EGFR. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that mediate RNA interference against EGFR.
Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
Abstract: Provided herein are targeted photoacoustic compounds and formulations thereof that can contain a photoacoustic signaling moiety operatively coupled to a targeting moiety. Also provided herein are methods of imagining a subject using the targeted photoacoustic compounds and formulations thereof provided herein.
Type:
Grant
Filed:
June 13, 2016
Date of Patent:
December 22, 2020
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.
Type:
Grant
Filed:
July 24, 2018
Date of Patent:
November 24, 2020
Assignee:
DUKE UNIVERSITY
Inventors:
Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
Abstract: Protected fluorescent reagent compounds and their methods of synthesis are provided. The compounds are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The compounds contain fluorescent dye elements, that allow the compounds to be detected with high sensitivity at desirable wavelengths, binding elements, that allow the compounds to be recognized specifically by target biomolecules, and protective shield elements, that decrease undesirable contacts between the fluorescent dye elements and the bound target biomolecules and that therefore decrease photodamage of the bound target biomolecules by the fluorescent dye elements.
Type:
Grant
Filed:
April 30, 2018
Date of Patent:
October 13, 2020
Assignee:
Pacific Biosciences of California, Inc.
Inventors:
Lubomir Sebo, Jeremiah Hanes, Gene Shen, Louis Brogley, Stephen Yue, Frank Zheng, Yuri Lapin, John Lyle, Honey Osuna, Andrei Fedorov
Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.
Type:
Grant
Filed:
September 14, 2017
Date of Patent:
October 6, 2020
Assignee:
Janssen BioPharma, Inc.
Inventors:
Sergei Gryaznov, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong, Rajendra K. Pandey, Vivek Kumar Rajwanshi, Lakshmipathi Pandarinathan, Yi Jin, Bharat Baral
Abstract: The present invention provides molecular constructs and methods for use thereof, including constructs including heterologous miRNA recognition sites, constructs for gene suppression including a gene suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence, constructs containing engineered miRNA or miRNA precursors, and constructs for suppression of production of mature microRNA in a cell. Also provided are transgenic plant cells, plants, and seeds containing such constructs, and methods for their use. The invention further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous. Also disclosed are novel miRNAs and miRNA precursors from crop plants including maize and soy.
Type:
Grant
Filed:
June 29, 2017
Date of Patent:
October 6, 2020
Assignee:
MONSANTO TECHNOLOGY LLC
Inventors:
Edwards M. Allen, Larry A Gilbertson, Sara E. Heisel, Shihshieh Huang, Elysia K. Krieger, Thomas M. Malvar
Abstract: A prokaryotic protein appearing to have a Bin/Amphiphysin/Rvs (BAR) domain, previously known in eukaryotes, has been identified. Expression of this protein causes formation of outer membrane extensions.
Type:
Grant
Filed:
May 24, 2019
Date of Patent:
October 6, 2020
Assignee:
The Government of the United States of America, as represented by the Secretary of the Navy
Abstract: Methods and compositions for serum-stabilizing micelles for drug delivery or imaging agent delivery are provided, as well as methods and compositions to enhance micelle-mediated drug delivery. This invention provides a process for synthesizing a lipid micelle comprising one or more lipid-oligonucleotide conjugate molecules, the process comprising contacting an amount of lipid molecules with an amount of lipid-oligonucleotide conjugate molecules sufficient to create a lipid micelle comprising lipid-oligonucleotide conjugate molecules.
Abstract: The invention relates to a novel VHH construct which can be bounded by a complete antibody without impairment of the antigen binding properties of the VHH construct being impaired. The invention also relates to an antibody construct comprising a VHH construct of this type and a kit, as well as the use thereof in immunodiagnostics or in the area of therapeutics. With the invention, among other things, it is possible to direct the existing immunity of a patient toward a different antigen.
Type:
Grant
Filed:
April 11, 2016
Date of Patent:
September 15, 2020
Assignee:
PRECLINICS GES. F. PRAEKLINISCHE FORSCHUNG MBH
Inventors:
Jonas Fuener, Angelo Bolchi, Erik Schliebs, Simone Ottonello
Abstract: The invention provides cotton event MON 88701, and plants, plant cells, seeds, plant parts, and commodity products comprising event MON 88701. The invention also provides polynucleotides specific for event MON 88701 and plants, plant cells, seeds, plant parts, and commodity products comprising polynucleotides specific for event MON 88701. The invention also provides methods related to event MON 88701.
Type:
Grant
Filed:
June 20, 2018
Date of Patent:
September 15, 2020
Assignee:
Monsanto Technology LLC
Inventors:
Ronald Joseph Brinker, Wen C. Burns, Paul C. C. Feng, John A. Kendig, Sherry LeClere, Jennifer Lutke, Marianne Malven
Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
Type:
Grant
Filed:
May 30, 2016
Date of Patent:
September 1, 2020
Assignee:
CureVac Real Estate GmbH
Inventors:
Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
Type:
Grant
Filed:
June 30, 2016
Date of Patent:
September 1, 2020
Assignee:
CITY OF HOPE
Inventors:
Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-151. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-151. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.
Type:
Grant
Filed:
June 2, 2014
Date of Patent:
August 11, 2020
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb, Xierong Wei
Abstract: Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.
Type:
Grant
Filed:
August 5, 2019
Date of Patent:
July 21, 2020
Assignees:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE TEXAS A&M UNIVERSITY SYSTEM
Inventors:
Lisa Bielke, Sherryll Layton, Billy Hargis, Neil R. Pumford, Olivia B. Faulkner, Luc Berghman, Daad Abi-Ghanem
Abstract: Various methods and systems for processing at least some of genome sequences and at least some of associated information, for an individual, may be described and disclosed herein. A purpose of such processing may be to prevent, minimize, and/or mitigate against (1) identification of the individual from such genome sequence information and/or from associated information; and/or (2) using such genome sequence information and/or associated information as a basis for discriminating against the individual.
Abstract: Disclosed herein are nucleotide sequences encoding an insecticidal protein exhibiting Lepidopteran inhibitory activity, as well as novel insecticidal proteins referred to herein as a BCW 001, BCW 002, BCW 003, and BCW toxic protein-containing chimeras and BCW toxin insecticide, transgenic plants expressing the chimeras or the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
July 7, 2020
Assignee:
Monsanto Technology LLC
Inventors:
James A. Baum, David J. Bowen, Catherine A. Chay, David J. Chi, William P. Clinton, Crystal L. Dart, Leigh English, Stanislaw Flasinski, Victor M. Guzov, Kevin A. Jarrell, Uma R. Kesanapalli, Thomas M. Malvar, Robert M. McCarroll, Jason S. Milligan, Jay P. Morgenstern, Deborah G. Rucker, Sara A. Salvador, Temple F. Smith, Carlos E. Soto, Collin M. Stultz, Brian M. Turczyk, Ty T. Vaughn, Moritz W. F. Von Rechenberg
Abstract: A method for optimising a nucleotide sequence for protein expression in a host cell, comprising the steps of: (a) constructing an expression library comprising a large number of variants of the sequence to be expressed operatively cloned in an expression vector, wherein (i) the sequence of the 6 nucleotides immediately upstream (5?-direction) of the first codon of the coding sequence to be expressed is completely or partially randomized; (ii) the sequence of the second and third codons of the coding sequence to be expressed is randomized, wherein the randomization of the second and third codons is limited to changes not altering the amino-acids encoded by said codons; (b) screening the library with regard to efficiency of protein expression in the host cell; and (c) selecting a sequence resulting in a desired level of efficiency of protein expression.
Type:
Grant
Filed:
December 15, 2015
Date of Patent:
June 30, 2020
Assignee:
CloneOpt AB
Inventors:
Daniel Daley, Kiavash Mirzadeh, Stephen Toddo, Suchithra Guntur
Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
Type:
Grant
Filed:
December 13, 2019
Date of Patent:
June 30, 2020
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The invention relates to a method and means for diagnosing tumors, in particular for an early diagnosis (prevention) and for differentiating between benign and malignant tumors using a PCR, in particular in bodily fluids. The method according to the invention is characterized by a combination of a pre-amplification process using a PCR, wherein methylated DNA sequences are amplified more strongly than non-methylated DNA sequences, and a subsequent quantification process using a special digital PCR, in which significantly more DNA is used than normally in the prior art. As comparison data indicates, the invention advantageously allows a clear reliable conclusion as to whether a malignant tumor disease is present or not. The invention is suitable for screening (prevention), monitoring the progress of a tumor disease, in particular to order to exclude a minimal residual disease (MRD), and for a differential diagnosis between malignant carcinoma and benign tumors.
Type:
Grant
Filed:
December 22, 2016
Date of Patent:
June 23, 2020
Assignee:
TECHNISCHE UNIVERSITĂ„T DRESDEN
Inventors:
Mario Menschikowski, Albert Hagelgans, Gabriele Siegert
Abstract: Aspects of the disclosure relate to methods of altering RNA splicing in a subject. In some embodiments, methods are provided for correcting splicing in a cell that contains a DYSF gene having a mutation that results in defective splicing.
Type:
Grant
Filed:
June 3, 2015
Date of Patent:
June 23, 2020
Assignee:
University of Massachusetts
Inventors:
Robert H. Brown, Jr., Janice A. Dominov
Abstract: A biosensing platform capable of high throughput mechanochemical biosensing comprising a DNA origami nanostructure having a plurality of slots into which recognition elements are strategically placed and apparatus that senses a change in the origami nanostructure in response to the introduction of a target where the apparatus includes a signal transduction unit and signal sensor which exploits mechanical signals in a recognition element which signal includes one or more mechanical tension or mechanochemical rearrangement event. The nanostructure is preferably a 2-dimensional or 3-dimensional arrangement of tiles linked by locking elements, such as aptamers that will open in response to an event such as exposure to a drug molecule, DNA, RNA or protein target.
Type:
Grant
Filed:
June 5, 2015
Date of Patent:
June 23, 2020
Assignee:
KENT STATE UNIVERSITY
Inventors:
Hanbin Mao, Deepak P. Koirala, Hiroshi Sugiyama, Masayuki Endo
Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
Abstract: The present disclosure describes a nanoparticle comprising a three dimensional DNA nanocage and a payload biological macromolecule, and methods of assembly thereof.
Type:
Grant
Filed:
July 13, 2017
Date of Patent:
June 2, 2020
Assignee:
Arizona Board of Regents on behalf of Arizona State University
Inventors:
Jinglin Fu, Zhao Zhao, Neal Woodbury, Hao Yan
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
June 2, 2020
Assignees:
The Regents of the University of California, University of Vienna
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
Type:
Grant
Filed:
August 27, 2018
Date of Patent:
May 26, 2020
Assignee:
TRUSTEES OF BOSTON UNIVERSITY
Inventors:
James J. Collins, Kyle R. Allison, Mark P. Brynildsen
Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).
Type:
Grant
Filed:
January 23, 2018
Date of Patent:
May 12, 2020
Assignee:
SomaLogic, Inc.
Inventors:
James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
Abstract: Described are post transcriptionally chemically modified double strand RNAs (MdsRNAs) having more than 30 base pairs. The MdsRNAs inhibit gene expression in target organisms. Also described are methods of making and using MdsRNAs.
Type:
Grant
Filed:
October 22, 2018
Date of Patent:
May 5, 2020
Assignee:
nanoSUR LLC
Inventors:
Juan P. Arhancet, Sreevishnu Cheerla, Graciela B. Arhancet, David B. Rozema
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
May 5, 2020
Assignees:
The Regents of the University of California, University of Vienna
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
Type:
Grant
Filed:
November 18, 2019
Date of Patent:
April 28, 2020
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
April 21, 2020
Assignee:
Translate Bio, Inc.
Inventors:
Michael Heartlein, Frank DeRosa, Anusha Dias
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
November 27, 2018
Date of Patent:
April 21, 2020
Assignees:
The Regents of the University of California, University of Vienna
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: The present disclosure is directed to an artificial mimic miRNA utilizing miRNA. An artificial mimic miRNA is a single-stranded nucleic acid including: a X region; and a Y region, the Y region and the X region being linked, wherein the X region is a guide strand sequence of a mature miRNA or a partial sequence of the guide strand sequence of the mature miRNA and consists of a linking side region (XB) and a non-linking side region (XF) to the Y region, the linking side region (XB) is a sequence that does not cause intramolecular annealing within its region, and the Y region is a sequence that intramolecularly anneals to the non-linking side region (XF) of the X region. According to the artificial mimic miRNA of the present invention, the expression of the target gene can be inhibited.
Abstract: The present disclosure relates to an expression vector for restoring male sterility in a plant. The expression vector comprises a regulatory region sequence operably linked to a heterologous nucleotide sequence.
Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides (AONs) that may be used in the treatment, prevention and/or delay of Usher syndrome type II and/or USH2A-associated non syndromic retina degeneration.
Type:
Grant
Filed:
September 22, 2017
Date of Patent:
April 7, 2020
Assignee:
ProQR Therapeutics II B.V.
Inventors:
Hester Catharina Van Diepen, Janne Juha Turunen, Hee Lam Chan
Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.
Type:
Grant
Filed:
June 26, 2019
Date of Patent:
March 31, 2020
Assignee:
Mologen AG
Inventors:
Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
Abstract: Chimeric double peptide vaccines are disclosed, useful for inducing active immunity against Candida fungal infections. The chimeric peptide comprises an Fba peptide and an Met6 peptide, covalently linked to one another, with or without an intermediate linker. Fba and Met6 are cell surface components of Candida. When used as a vaccine, the chimeric double peptide vaccine induces stronger protective immunity against fungal infection than does the Fba peptide alone, or the Met6 peptide alone, or a mixture (not covalently linked) of the two peptides.
Type:
Grant
Filed:
June 19, 2015
Date of Patent:
March 17, 2020
Assignee:
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Abstract: This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.
Type:
Grant
Filed:
October 4, 2017
Date of Patent:
March 17, 2020
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
William R. Taylor, Jonathan J. Harrington, Patrick S. Quint, Hongzhi Zou, Harold R. Bergen, III, David I. Smith, David A. Ahlquist
Abstract: An object of the present invention is to conduct a search for a compound to be arranged at a terminal of a peptide nucleic acid effective in detecting a single nucleotide polymorphism. Provided is a tolan compound represented by the following formula (1): wherein R1 represents a phenyl group or a naphthyl group, the phenyl group may have 1 to 5 substituents that are identical to or different from each other, and the naphthyl group may have 1 to 7 substituents that are identical to or different from each other.
Abstract: The present invention relates to core-shell particles comprising encapsulated nucleic acids—a sensing sequence and a control sequence; the invention further relates to the use of such particles as a sensing element; to methods for measuring a property of interest in a setting employing such particles; to measuring systems and analytical kits comprising such particles.
Type:
Grant
Filed:
April 19, 2016
Date of Patent:
March 3, 2020
Assignee:
ETH Zurich
Inventors:
Robert N. Grass, Wendelin Jan Stark, Gediminas Mikutis, Michela Puddu
Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
Type:
Grant
Filed:
July 22, 2016
Date of Patent:
February 18, 2020
Assignees:
INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ONXEO, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS-SUD 11
Abstract: Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.
Type:
Grant
Filed:
May 10, 2018
Date of Patent:
January 28, 2020
Assignee:
SomaLogic Inc.
Inventors:
Nebojsa Janjic, Daniel W. Drolet, Amy D. Gelinas, Chi Zhang, Michael Vrkljan
Abstract: Provided herein, inter alia, are double stranded oligonucleotide molecules and methods of making the molecules. The double stranded oligonucleotide molecules include a first oligonucleotide strand comprising a first nucleic acid sequence bound to a second nucleic acid sequence through a first spacer, wherein said second nucleic acid sequence is bound to a third nucleic acid sequence through a second spacer and a second oligonucleotide strand comprising a fourth nucleic acid sequence bound to a fifth nucleic acid sequence through a third spacer, wherein said fifth nucleic acid sequence is bound to a sixth nucleic acid sequence through a fourth spacer, wherein the second nucleic acid sequence and the fifth nucleic acid sequence are hybridized to form a double stranded nucleic acid core of said double stranded oligonucleotide.
Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules such as chikungunya viral proteins, such as chikungunya envelope protein E1.
Abstract: A method of detecting the presence of Neisseria gonorrhoeae in a sample. The method involves detecting a first target sequence taken from the NGO1642 gene and/or a second target sequence taken from the NGO1012 gene. The method may involve a step of amplifying the target sequence, and may involve hybridising the target sequence to a nucleic acid probe and identifying hybridisation. The method may involve simultaneous detection of other target sequences, e.g. from other pathogens.
Type:
Grant
Filed:
September 17, 2015
Date of Patent:
December 31, 2019
Assignee:
Atlas Genetics Limited
Inventors:
Danny Filer, Claire Ferrao, Sharon Chadwick
Abstract: Devices and methods for detecting, identifying, and sequencing, compounds, complexes, and molecules are described. Electronic detection is combined with optical excitation to determine the presence or identity of an analyte of interest. Embodiments of the invention additionally provide devices and methods that allow highly parallel nucleic acid sequence determination.